# Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)

> **NCT00637195** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 152 (actual)

## Conditions studied

- Infections, Papillomavirus
- Papillomavirus Vaccines

## Interventions

- **BIOLOGICAL:** Subjects received 3 doses of GSK Biologicals' HPV vaccine (580299) (Cervarix™)
- **BIOLOGICAL:** Engerix™

## Key facts

- **NCT ID:** NCT00637195
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03-11
- **Primary completion:** 2008-06-20
- **Final completion:** 2009-06-18
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2020-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00637195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00637195, "Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00637195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*